Venetoclax in combination with carfilzomib and dexamethasone in relapsed/refractory multiple myeloma harboring t(11,14)(q13;q32): two case reports and a review of the literature

BACKGROUND: Multiple myeloma has witnessed significant advances due to the approval of many novel agents. However, in spite of all these new developments, multiple myeloma remains an incurable disease with inevitable relapse in the majority of patients. Venetoclax is a selective antiapoptotic protei...

Descripción completa

Detalles Bibliográficos
Autores principales: Abuelgasim, Khadega A., Alherz, Noha, Alhejazi, Ayman, Damlaj, Moussab
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2020
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7178736/
https://www.ncbi.nlm.nih.gov/pubmed/32321588
http://dx.doi.org/10.1186/s13256-020-02376-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7178736/
https://www.ncbi.nlm.nih.gov/pubmed/32321588
http://dx.doi.org/10.1186/s13256-020-02376-y

Ejemplares similares